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Abstract Childhood adrenocortical tumor (ACT), a very
rare malignancy, has an annual worldwide incidence of
about 0.3 per million children younger than 15 years. The
association between inherited germline mutations of the
TP53 gene and an increased predisposition to ACT was
described in the context of the Li-Fraumeni syndrome. In
fact, about two-thirds of children with ACT have a TP53
mutation. However, less than 10% of pediatric ACT cases
occur in Li-Fraumeni syndrome, suggesting that inherited
low-penetrance TP53 mutations play an important role in
pediatric adrenal cortex tumorigenesis. We identiﬁed a
novel inherited germline TP53 mutation affecting the
acceptor splice site at intron 10 in a child with an ACT and
no family history of cancer. The lack of family history of
cancer and previous information about the carcinogenic
potential of the mutation led us to further characterize it.
Bioinformatics analysis showed that the non-natural and
highly hydrophobic C-terminal segment of the frame-
shifted mutant p53 protein may disrupt its tumor suppressor
function by causing misfolding and aggregation. Our
ﬁndings highlight the clinical and genetic counseling
dilemmas that arise when an inherited TP53 mutation is
found in a child with ACT without relatives with
Li-Fraumeni-component tumors.
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ACT Adrenocortical tumor
DBD DNA-binding domain
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IARC International Agency for Research on Cancer
NES Nuclear export signal
Introduction
Adrenocortical tumors (ACTs) occur rarely in children and
have an estimated incidence of only 0.3 per million in
individuals younger than 15 years [1]. Although several
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TP53 mutations account for most cases. Children with
ACT, particularly when it is diagnosed before the child’s
ﬁfth birthday, commonly carry an inherited TP53 mutation
[2]. The association between pediatric ACT and germline
TP53 mutations is so strong that ACT is now considered an
independent criterion to obtain TP53 genetic testing and
counseling [3]. The vast majority of germline mutations
that increase the predisposition to cancer occur within the
DNA binding domain (DBD) and usually abrogate TP53
sequence-speciﬁc DNA-binding activity [4]. Individuals
who carry these mutations have more than an 80% risk of
cancer during their lifetime and are usually tested for TP53
because of a remarkable family history of cancer (Li-
Fraumeni and Li-Fraumeni-like syndrome). The core
component tumors in Li-Fraumeni syndrome include adre-
nocortical, brain, and breast tumors; soft tissue and bone
sarcomas; and acute leukemia. Recently, low-penetrance
TP53 mutations have been found to increase the predispo-
sition for ACT outside of the context of Li-Fraumeni syn-
drome, suggesting that the adrenal cortex is particularly
sensitive to TP53 inactivation. Therefore, as more low-
penetrance mutations are revealed, the critical issue is to
determine their clinical relevance.
Here we report a novel inherited germline TP53 muta-
tion affecting the acceptor splice site at intron 10 in a
pediatric patient with an ACT and no family history of
cancer. Our ﬁndings highlight the importance of analyzing
the transcripts encoded by mutant TP53 genes in tumor
tissue and reinforce the role of TP53 inactivation in pedi-
atric ACT.
Materials and methods
The patient and her parents consented to participate in the
St. Jude Children’s Research Hospital International Pedi-
atric Adrenocortical Tumor Registry following the insti-
tutional review board-approved research protocol.
Pathologic and immunostaining analysis
This ACT was evaluated according to the following path-
ologic criteria: tumor size and weight, nuclear grade,
mitotic rate per 50 high-power ﬁelds, tumor cell cytoplasm
(0–25% and 26–100% clear) and architecture (diffuse and
nondiffuse), presence or absence of atypical mitoses,
necrosis, and unequivocal capsular, venous, sinusoidal, and
adjacent organ invasion. Formalin-ﬁxed, parafﬁn-
embedded tissue sections 5 lm thick were processed for
histologic and immunohistochemical analysis. Immuno-
histochemical sections were analyzed using the avidin–
biotin complex method. Commercially available antibodies
speciﬁc for vimentin, synaptophysin, chromogranin A,
inhibin, melan A, pancytokeratin, Ki-67, and p53 protein
were used. Immunohistochemical staining was classiﬁed as
negative (no immunopositivity), weak (up to 25% of cells
immunopositive), moderate (between 25 and 70% of cells
immunopositive), or strong (more than 70% of cells im-
munopositive), and cellular localization was classiﬁed as
cytoplasmic or nuclear. A rabbit or mouse (Dako, Car-
pinteria, CA, USA) universal negative control was used as
the negative control for each speciﬁc antibody.
Sequencing analysis
Genomic DNA was isolated from peripheral blood leuko-
cytes and tumor samples using standard protocols. TP53
exons 2–11, including the intron sequence ﬂanking each
exon, were ampliﬁed by polymerase chain reaction (PCR)
and submitted to high-throughput DNA sequencing using a
3730 xl DNA Analyzer (Applied Biosystems, Foster City,
CA, USA). Primer sequences are available upon request,
and PCR conditions were as follows: 94C for 10 min; 35
cycles of 94, 60, and 72C for 30 s each; and 72C for
7 min. The sequence plots were compared to a normal
sequence (National Center for Biotechnology Information,
accession number NC_000017).
Reverse transcription PCR analysis
Total RNA was isolated from ACT tissue using a Qiagen
RNeasy Midi Kit (Qiagen Sciences, Gaithersburg, MD,
USA). Reverse transcription reactions were run with 1 lg
of total RNA using the iScript cDNA Synthesis Kit (Bio-
Rad Laboratories, Hercules, CA, USA) according to the
manufacturer’s instructions. This cDNA was ampliﬁed
using speciﬁc sets of primers covering exon 10 through the
wild-type stop codon signal at exon 11. Other primer sets
were designed to conﬁrm the mutation and the novel stop
codon signal at the 30-untranslated region of the TP53 gene.
Protein analysis
The program JPRED3 [5] (available at www.compbio.
dundee.ac.uk/www-jpred/) was used to predict the polypep-
tide secondary structure for wild-type p53 and the frame-
shifted mutant p53.
Results
Case report
A previously healthy girl of Filipino descent, 2 years and
8 months old, had a 4-week history of rounding of her face,
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123acne on her forehead, an increased appetite, and weight
gain of 3.2 kg. Two weeks later, signs of virilization were
noted. The maternal grandfather and his brother, both
reported to be heavy smokers, died from lung cancer in
their 50s. On admission, the patient weighed 16.7 kg
(percentile, 95.7) and was 95 cm tall (percentile, 58). Her
blood pressure was 142/92 on admission. She had a
Cushingoid build with round moon facies and truncal
obesity. No abdominal masses were palpable. She had acne
on the forehead and increased oiliness of the facial skin.
There was no axillary hair and no breast development. The
genitalia showed signs of virilization. Laboratory tests
revealed 5-dehydroepiandrosterone at 4546 ng/dL (normal,
19–42), testosterone at 84 ng/dL (normal,\10), and cor-
tisol at 35.1 lg/dL at 8:00 AM and 32.3 lg/dL at midnight
(normal,\5). Abdominal computed tomography con-
ﬁrmed the ﬁnding of a 4.5 9 4.0 9 4.0 cm right adrenal
mass. The mass, involving the right adrenal gland, dis-
placed the kidney inferiorly. The mass was smoothly
marginated and appeared fairly vascular with heteroge-
neous enhancement.
The patient underwent exploratory surgery through a
right subcostal incision. The mass was removed intact
without violation of its capsule. Postoperatively, her
Cushingoid features resolved, and she lost 1.4 kg in
3 months despite adequate oral hydrocortisone therapy. All
of her laboratory markers normalized. To date, there has
been no evidence of a recurrence clinically, biochemically,
or sonographically.
Histopathologic ﬁndings
The tumor weighed 48 g and measured 4.5 9 4.0 9
4.0 cm. Surgical margins were negative. No necrosis and
no vascular invasion were observed. Microscopic analysis
revealed the presence of multiple atypical and multipolar
mitotic ﬁgures (Fig. 1, Panel A). Immunohistochemistry
showed strong cytoplasmic staining for vimentin (Fig. 1,
Panel B), inhibin (Fig. 1, Panel C), synaptophysin, and
melan A and moderate cytoplasmic staining for p53 protein
(Fig. 1, Panel D). Strong nuclear immunostaining for Ki-67
was present in 10–15% of tumor cells. Immunostaining for
chromogranin A, pancytokeratin, and nuclear p53 protein
was negative. Findings are consistent with typical features
of ACT.
Identiﬁcation of a germline TP53 splice-site mutation
Genomic DNA from ACT tissue from this patient harbored
a homozygous TP53 alteration at the junctions of intron 10
Fig. 1 (Panel A) Cellular tumor with eosinophilic cells with prominent nuclear pleomorphism and increased mitosis. Immunohistochemistry
showed the tumor cells were positive for vimentin (Panel B), inhibin A (Panel C), and cytoplasmic p53 protein (Panel D)
TP53 mutation in a pediatric adrenocortical tumor 143
123and exon 11, and the same was observed in the heterozy-
gous state in genomic DNA from peripheral blood leuko-
cytes, indicating a loss of heterozygosity for this locus
(Fig. 2, Panels B1 and B2). This mutation was also present
in genomic DNA in the heterozygous state from the
patient’s mother. The father had the wild-type TP53 gene
sequence. This alteration represents a change in the
nucleotides AG at the splice acceptor site in intron 10
(IVS10-2 A[G), necessary for correct pre-mRNA pro-
cessing, and could result in aberrant splicing. Tumor
mRNA was examined for alternate splicing by reverse
transcription PCR. The resulting cDNA was ampliﬁed
using primers that covered exon 10 through the normal stop
codon of the TP53 gene and was found to have a deletion
of the initial 10 bp of exon 11 (Fig. 2, Panels C1 and C2).
This 10-bp deletion causes a frame shift and predicts a new
termination signal, 82 base pairs after that of the wild type.
Another PCR analysis was performed using another set of
primers covering exon 10 through this new stop codon, and
the results showed a transcript with the corresponding size
and sequence analysis conﬁrmed the results. Because of the
10-bp deletion, frame shift, and new stop codon location,
this polypeptide segment was completely different from the
wild type in terms of its sequence and number of amino
acid residues and resulted in a new C-terminal motif in
transcripts for the mutant TP53 sequence. Schematic rep-
resentations of the 30-terminal region of the wild type and
mutated TP53 gene are shown in Fig. 2, Panels A1 and A2.
Splice mutation predicts an intrinsically unstructured
domain for p53 protein
The C-terminal regulatory domain of TP53 is intrinsically
disordered [6], has post-translational modiﬁcation at
numerous sites, and interacts with numerous signaling
partners [7]. The amino acid composition of the mutated,
frame-shifted C-terminal domain is radically different from
that of the wild-type domain; therefore, this mutant domain
is unlikely to regulate TP53 function in response to cellular
signals. Furthermore, the sequence of the mutant C-
terminal domain is inconsistent with that of normal, func-
tional proteins (for example, 48% of the amino acids are
Fig. 2 Panel A1—Schematic representation of the 30-terminal region
of the wild-type TP53 gene. Panel A2—The mutation eliminates the
wild-type TP53 acceptor site at the junction of intron 10 and exon 11.
An internal AG acceptor site within exon 11 is selected resulting in
deletion of a 10-bp sequence (ccacctgaag), a frame-shift and an alter-
native stop codon signal. Panel B1—Heterozygous TP53 sequence in
peripheral blood lymphocyte DNA. Panel B2—Homozygous mutant
TP53 sequence (loss of heterozygosity) in tumor DNA. Panel C1—
cDNA of a normal individual (wild-type sequence). Panel C2—
Patient’s tumor cDNA sequence (deletion of the ﬁrst 10 bp of exon
11)
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123either proline [20%], leucine [18%], or serine [10%]) and
with formation of a secondary structure (a-helix or
b-sheet), based on analysis using JPRED3 [5]. The unnat-
urally high content of proline and leucine residues may
confer a propensity for the full-length, frame-shifted
mutant p53 protein to misfold and aggregate. In conclu-
sion, the non-natural and highly hydrophobic C-terminal
segment of the frame-shifted mutant p53 protein may dis-
turb tumor suppressor function by causing a loss of regu-
latory function, misfolding. and aggregation.
Discussion
We found a novel inherited germline TP53 acceptor splice-
site mutation at the junction of intron 10 and exon 11 in a
child with ACT. The loss of heterozygosity selecting
against the wild-type TP53 allele in tumor tissue suggests
that this mutation played a role in adrenal tumorigenesis in
this case. Germline or somatic TP53 splice-site mutations
have rarely been described in association with cancer
[8, 9]. Furthermore, the mutation we report here has not
been recorded in the International Agency for Research on
Cancer (IARC) TP53 mutation database (www.iarc.fr).
Because most germline TP53 mutations registered in the
IARC database are from individuals from families with
cancer-prone syndromes, it is possible this TP53 splice
mutation, similar to other low-penetrance TP53 mutations,
is not associated with well-deﬁned familial cancer syn-
dromes and may not be detected until revealed in associ-
ation with TP53-core tumors such as pediatric ACT. The
association between low-penetrance mutations and tumor-
igenesis of the developmental adrenal cortex has been
amply documented [10, 11], to the extent that the diagnosis
of ACT alone is now considered a criterion for TP53
testing [3]. In this regard, many of the inherited germline
low-penetrance TP53 mutations revealed in children with
ACT [12] or choroid plexus tumors [13] may not increase
carriers’ predisposition to Li-Fraumeni-component tumors.
In fact, in the IARC database, only about 7.8% of cases of
ACT registered have a family history of Li-Fraumeni
syndrome. This contrasts with 32.2% with a family history
of Li-Fraumeni syndrome when the proband has breast
cancer. The ﬁnding of an inherited novel TP53 mutation in
a child with ACT creates a dilemma, as this tumor can be
associated with either DBD or low-penetrance mutations
and therefore has substantial implications for genetic
counseling.
Consistent with the interpretation that this TP53 splice
mutation is of low penetrance is that the family history of
cancer of this child is not typical of Li-Fraumeni syndrome
[14, 15]. The mother, who is in her 30s and carries the
mutation, has not been affected by cancer. Moreover only
two cases of cancer have been reported in her family: her
father and his brother; both heavy smokers whose cancer
was diagnosed when they were in their 50s. However, the
clinical-epidemiologic data of the family are limited;
hence, it is plausible that the TP53 splice mutation may
have tumorigenic potential similar to TP53 mutations that
affect the DBD. First, the mother is still young and at risk
for TP53-core-component cancers such as breast or brain
tumors and soft tissue or bone sarcomas. Secondly, the
familial cancer history may be incomplete, because many
members of this family reside in the Philippines, and we
did not have access to their medical records. Finally, lung
and other cancers, although not included in the Li-
Fraumeni syndrome criteria, may occur in carriers of TP53
DBD mutations. Of interest, lung cancer was the most
common cancer type in carriers of germline TP53 muta-
tions who did not develop Li-Fraumeni-component tumors
[16]. Therefore, given the lack of information on the TP53
splice mutation and detailed clinical-epidemiologic data, it
is not possible to determine whether the carriers of this
mutation have an increased predisposition to cancer, as
seen in individuals who carry TP53 mutations that disrupt
the DBD of the protein.
In an attempt to further elucidate the functional char-
acteristics of this mutation, which altered a region
responsible for pre-mRNA processing, we performed
transcriptome analysis. Sequencing of the TP53 transcripts
obtained from RNA extracted from tumor tissue revealed
that a new acceptor site was utilized, eliminating the ﬁrst
10 bp of exon 11 and leading to a frame shift and an altered
stop codon. The new sequence of exon 11 predicts a
polypeptide different from that of the wild type in sequence
and number of residues, resulting in alterations in the
protein’s C-terminal region. Bioinformatics analysis of the
structural features of the frame-shifted mutant p53 protein
suggested that the non-natural C-terminal domain may
cause misfolding and aggregation, therefore inhibiting
tumor suppressor function. As noted earlier, the C-terminal
domain plays a critical role in regulating TP53 function.
For example, the region between residues 363 and 393 has
been referred to as an apoptotic domain [17]. C-terminally
deleted p53 protein has weaker apoptosis-inducing activity
than intact TP53 [18]. Furthermore, previous studies have
shown that the ability of the isolated C-terminus to form
stable tetramers in vitro is facilitated by the phosphoryla-
tion of its penultimate serine residue. Stabilization of tet-
ramers may not only increase DNA binding but also may
help to keep p53 in the nucleus by masking its nuclear
export signal (NES) sequence [19]. The C-terminus of the
frame-shifted mutant p53 protein reported here has a high
leucinecontentandhydrophobiccharacterthatﬁtsthecriteria
established for an intrinsic NES [20]. An intrinsic NES
mediatesthesubcellularlocalizationandnuclear-cytoplasmic
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123shuttlingofp53throughanassociationwithanexportreceptor
[19], consistent with cytoplasmic p53 immunostaining
observed in this case. Taken together, the transcriptome
analysis suggests that this mutation causes a loss of tumor
suppressorfunctionthroughavarietyofmechanisms,perhaps
toanextentsimilartothatassociatedwithDBDmutationsand
with similar clinical-pathologic consequences.
In summary, the type of malignancy associated with this
patient, her family history of cancer, TP53 genetic testing
ﬁndings, and predictive analysis of the mutant protein
highlight the complexity of the relationship between TP53
mutations and malignancy. Careful consideration of these
factors is critical for appropriate patient management and
genetic counseling.
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